梯瓦制药Teva Pharmaceutical Industries Limited (TEVA) 2017年年度报告「NYSE」.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31,2017 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES E

2、XCHANGE ACT OF 1934For the transition period from to Commission file number 001-16174TEVA PHARMACEUTICAL INDUSTRIES LIMITED(Exact name of registrant as specified in its charter)Israel Not Applicable(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)5 Basel

3、 Street,Petach Tikva,ISRAEL,4951033(Address of principal executive offices and Zip Code)+972(3)914-8171(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:American Depositary Shares,each representing one Ordinary Share New York Stock Exchange(T

4、itle of each class)(Name of each exchange on which registered)Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not req

5、uired to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding12 months(or for such shorter period that the reg

6、istrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90days.Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submittedand post